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The indiscriminate use of ciprofloxacin for the treatment of
typhoid fever has been accompanied by a frightening
increase in the number of resistant cases. Isolates of
Salmonella Typhi with reduced susceptibility to ciproflox-
acin (as indicated by an increase in minimum inhibitory
concentration (MIC)), but still within the current Clinical
and Laboratory Standards Institute (CLSI) range for suscept-
ibility (1 mg/ml), have appeared in the Indian subconti-
nent and other regions.1,2 Reduced susceptibility to
ciprofloxacin is mediated by a single mutation in the gyrA
gene.3
A study was conducted at our center on 127 Salmonella
isolates obtained from blood cultures of patients during the
period January 2006 to May 2007 to determine the MIC of
ciprofloxacin by agar dilution method.4 The concentrations
used were doubling dilutions of ciprofloxacin from
0.0625 mg/ml to 32.0 mg/ml. The antibiotic susceptibilities
of ciprofloxacin and nalidixic acid were also determined by
Kirby—Bauer disc diffusion technique.
An increase in the MIC for ciprofloxacin (0.125—2.0 mg/ml)
was noted despite 100% susceptibility by disc diffusion
method (Table 1). Resistance to nalidixic acid was high
(95.4% for Salmonella Typhi and 92.5% for Salmonella Para-
typhi A). Nalidixic acid resistance is a marker for predicting
low-level resistance to ciprofloxacin and also an indicator of
treatment failure.
During 1989—90, there were reports of fever subsiding
after a mean of 3 days of ciprofloxacin therapy.5 From 1993,
reports of fever subsiding only after 5—6 days of treatment
appeared.6 In one community-based study, 21.9% of cases
took longer than 8 days to become afebrile and 9% did not
respond even after 15 days of treatment, despite in vitro
susceptibility.7 In a study conducted on patients from seven
US states, patients with Salmonella Typhi infection withTable 1 Minimum inhibitory concentration (MIC) values of ciprofl
Organism No. of strains showing MIC (mg
0.0625 0.125
Salmonella Paratyphi (40) — 9
Salmonella Typhi (87) — 6
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clearance time of 90 hours, as compared with patients
infected with isolates with ciprofloxacin MICs <0.12 mg/
ml where it was 64 hours.8 In another study, Salmonella
Typhi was recovered from blood after 6 days of ciproflox-
acin therapy in 17.4% of the patients who experienced
treatment failure.9
The use of high ciprofloxacin breakpoints not only mis-
guides clinicians, but also affects the surveillance of resis-
tance to this important drug and thus hinders the formulation
of policies for rational drug usage. Hence, to minimize the
probability of clinical failure or delayed response, and to
assess the true magnitude of antibiotic resistance, a lower
breakpoint for ciprofloxacin is recommended. Booker et al.
suggested susceptible breakpoints of 0.12 mg/ml in an in
vitro infection model.10 Moreover, changing susceptibility
breakpoints will negate the need for the use of the nalidixic
acid screening test.
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